Boston Scientific has acquired Asthmatx, the developer of a bronchial thermoplasty procedure marketed as an alternative to inhaled medications for the treatment of severe asthma for an upfront payment of $193.5 million and future payments of up to $250 million. The Alair Bronchial Thermoplasty System, which was approved by the FDA in April 2010, uses heat to … [Read more...] about Boston Scientific buys Asthmatx, hopes to expand use of bronchial thermoplasty
Medical
MAP announces Levadex trial results
A PD study has shown no statistically significant difference in pulmonary artery pressure effects of Levadex inhaled dihydroergotamine (DHE) compared to placebo, according to MAP Pharmaceutical. The inhaled formulation had a smaller effect on pulmonary artery pressure than IV DHE. MAP has said that it intends to submit an NDA for Levadex for the treatment of … [Read more...] about MAP announces Levadex trial results
Acetaminophen (paracetamol) doubles asthma risk
A study published in the American Journal of Respiratory and Critical Care Medicine found that teenagers who used acetaminophen at least once a month have a 250% higher risk of developing asthma than do non-users and nearly as great an increased risk of developing rhinoconjunctivitis. Read the abstract. … [Read more...] about Acetaminophen (paracetamol) doubles asthma risk